154 related articles for article (PubMed ID: 25760409)
1. Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.
Wityak J; McGee KF; Conlon MP; Song RH; Duffy BC; Clayton B; Lynch M; Wang G; Freeman E; Haber J; Kitchen DB; Manning DD; Ismail J; Khmelnitsky Y; Michels P; Webster J; Irigoyen M; Luche M; Hultman M; Bai M; Kuok ID; Newell R; Lamers M; Leonard P; Yates D; Matthews K; Ongeri L; Clifton S; Mead T; Deupree S; Wheelan P; Lyons K; Wilson C; Kiselyov A; Toledo-Sherman L; Beconi M; Muñoz-Sanjuan I; Bard J; Dominguez C
J Med Chem; 2015 Apr; 58(7):2967-87. PubMed ID: 25760409
[TBL] [Abstract][Full Text] [Related]
2. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
3. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.
Palmer WS; Alam M; Arzeno HB; Chang KC; Dunn JP; Goldstein DM; Gong L; Goyal B; Hermann JC; Hogg JH; Hsieh G; Jahangir A; Janson C; Jin S; Ursula Kammlott R; Kuglstatter A; Lukacs C; Michoud C; Niu L; Reuter DC; Shao A; Silva T; Trejo-Martin TA; Stein K; Tan YC; Tivitmahaisoon P; Tran P; Wagner P; Weller P; Wu SY
Bioorg Med Chem Lett; 2013 Mar; 23(5):1486-92. PubMed ID: 23352510
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration.
Bowers S; Truong AP; Jeffrey Neitz R; Hom RK; Sealy JM; Probst GD; Quincy D; Peterson B; Chan W; Galemmo RA; Konradi AW; Sham HL; Tóth G; Pan H; Lin M; Yao N; Artis DR; Zhang H; Chen L; Dryer M; Samant B; Zmolek W; Wong K; Lorentzen C; Goldbach E; Tonn G; Quinn KP; Sauer JM; Wright S; Powell K; Ruslim L; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
Bioorg Med Chem Lett; 2011 Sep; 21(18):5521-7. PubMed ID: 21813278
[TBL] [Abstract][Full Text] [Related]
5. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.
Noël R; Shin Y; Song X; He Y; Koenig M; Chen W; Ling YY; Lin L; Ruiz CH; LoGrasso P; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2011 May; 21(9):2732-5. PubMed ID: 21185177
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-substituted 7-azaindoles as Pan-PIM kinase inhibitors - Lead series identification - Part II.
Barberis C; Moorcroft N; Pribish J; Tserlin E; Gross A; Czekaj M; Barrague M; Erdman P; Majid T; Batchelor J; Levit M; Hebert A; Shen L; Moreno-Mazza S; Wang A
Bioorg Med Chem Lett; 2017 Oct; 27(20):4735-4740. PubMed ID: 28927793
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK.
Hom RK; Bowers S; Sealy JM; Truong AP; Probst GD; Neitzel ML; Neitz RJ; Fang L; Brogley L; Wu J; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Quinn K; Sauer JM; Powell K; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
Bioorg Med Chem Lett; 2010 Dec; 20(24):7303-7. PubMed ID: 21071223
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1
Oh Y; Jang M; Cho H; Yang S; Im D; Moon H; Hah JM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):372-376. PubMed ID: 31856610
[TBL] [Abstract][Full Text] [Related]
11. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design.
Wang X; Magnuson S; Pastor R; Fan E; Hu H; Tsui V; Deng W; Murray J; Steffek M; Wallweber H; Moffat J; Drummond J; Chan G; Harstad E; Ebens AJ
Bioorg Med Chem Lett; 2013 Jun; 23(11):3149-53. PubMed ID: 23623490
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
14. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
15. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
16. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
[TBL] [Abstract][Full Text] [Related]
17. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
Toledo-Sherman LM; Prime ME; Mrzljak L; Beconi MG; Beresford A; Brookfield FA; Brown CJ; Cardaun I; Courtney SM; Dijkman U; Hamelin-Flegg E; Johnson PD; Kempf V; Lyons K; Matthews K; Mitchell WL; O'Connell C; Pena P; Powell K; Rassoulpour A; Reed L; Reindl W; Selvaratnam S; Friley WW; Weddell DA; Went NE; Wheelan P; Winkler C; Winkler D; Wityak J; Yarnold CJ; Yates D; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2015 Feb; 58(3):1159-83. PubMed ID: 25590515
[TBL] [Abstract][Full Text] [Related]
18. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
19. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
[TBL] [Abstract][Full Text] [Related]
20. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
